NRG BN010

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain

Status:

Temporarily Closed

A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

NCT#04729959

BN010 , dose level 3 is temporarily closed to accrual, effective August 8, 2023.